Identification and susceptibility against fluconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge;Identificación y sensibilidad frente a fluconazol y albaconazol de 100 cepas de levaduras aisladas de flujo vaginal

Revista Iberoamericana de Micologia

Volumn 24, Issue 4, 2007, Pages 305-308

  Arechavala, Alicia I ^a   Bianchi, Mario H ^a   Robles, Ana María ^a   Santiso, Gabriela ^a   Negroni, Ricardo ^a  

^a HOSPITAL F J MUÑIZ   (Argentina)

Author keywords

Albaconazole; Fluconazole; Vulvovaginal candidiasis

Indexed keywords

ALBACONAZOLE; FLUCONAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA HOLMII; CANDIDA INCONSPICUA; CANDIDA INTERMEDIA; CANDIDA KRUSEI; FEMALE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TRICHOSPORON ASAHII; VAGINA CANDIDIASIS; VAGINA DISCHARGE;

CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA INCONSPICUA; CANDIDA INTERMEDIA; ISSATCHENKIA ORIENTALIS; SACCHAROMYCES EXIGUUS; TRICHOSPORON ASAHII;

EID: 38349136231     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(07)70061-X     Document Type: Article

References (29)

1. Alves SH, Da Matta DA, Azevedo AC, Loreto ES, Boff E, Santurio JM, Guarro J. In vitro activities of new and conventional antimycotics against fluconazole-susceptible and non-susceptible Brazilian Candida spp. isolates. Mycoses 2006; 49: 220-225.
2. Barrenetxea Ziarrusta G. Vulvovaginitis candidiásica. Rev Iberoam Micol 2002; 19: 22-24.
3. Buscemi L, Arechavala A, Negroni R. Estudio de las vulvovaginitis agudas en pacientes adultes, sexualmente activas, con especial referenda a la candidiasis, en pacientes del Hospital de Infecciosas F.J. Muñiz. Rev Iberoam Micol 2004; 21: 177-181.
4. Cardona Castro N, Revankar SG, Ortiz P, Cuervo C, Kirkpatrick WR, McAtee RK, Patterson TF. Proteinase detection, DNA typing and antimycotic susceptibility of Candida isolates from Colombian women with vulvovaginal candidiasis. Rev Iberoam Micol 2002; 19: 89-94.
5. Chen A, Sobel JD. Emerging azole antifungals. Expert Opin Emerg Drugs 2005; 10: 21-33.
6. Costa M, Lisboa Fernandes O de F, Rodrigues Silva MR. Candidiase vulvovaginal: aspectos clínicos, tratamento oral e susceptibilidade "in vitro". Rev Patol Trop 2003; 32: 145-162.
7. Eckert LO, Hawes SE, Stevens CE, Koutsy LA, Eschenbach DA, Colmes KK. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obste Gynecol 1998; 92: 757-765.
8. Foxman B. The epidemiology of vulvovaginal candidiasis: Risk factors. Amer J Publ Health 1990; 80: 329-331.
9. García Heredia, M, García SD, Copolillo EF, Cora Eliseth M, Barata AD, Vay CA, Torrres RA, Tiraboschi N, Famiglietti AMR. Prevalencia de candidiasis vaginal en embarazadas. Identificación de levaduras y sensibilidad a los antifúngicos. Rev Arg Microbiol 2006; 38: 9-12.
10. Jitsuron S, Kiamsini S, Pattararagron N. Milk medium for germ tube and chlamydoconidiae production by Candida. Mycopathologia 1993; 123: 95-98.
11. Linares Sicilia MJ, Solís Cuesta F. Identificación de levaduras. En: Pemán J, Martín-Mazuelos E, Rubio Calvo MC (Eds.) Guía práctica de identificación y diagnóstico en micología clínica. Bilbao, Revista Iberoamericana de Micología, 2001: 11-1 11-11.
12. Lopes Consolaro ME, Aline Albertoni T, Shizue Yoshida C, Mazucheli J, Peralta RM, Estivalet Svidzinski TI. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringa, Parana, Brazil. Rev Iberoam Micol 2004; 21: 202-205.
13. Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK Jr, Bartroli J, Perfect JR. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents And Chemother 2004; 48: 384-387.
14. Morera López Y, Torres Rodriguez JM, Jimenez Cabello T, Baro Tomas, T. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med Mycol 2005; 43: 505-510.
15. Mujica MT, Finquelievich JL, Jewtuchowicz V, Iovannitti CA. Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clínicas. Período 1999-2001. Rev Arg Microbiol 2004; 36: 107-112.
16. Muriel MA, Vizcaino MJ, Bilbao R, Herruzo R. Identificación de levaduras y sensiblidad "in vitro" a diversos antifúngicos. Enferm Infecc Microbiol Clin 2000; 18: 120-124.
17. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, Second Edition M27-A2. Villanova, National Committee for Clinical Laboratory Standards, 2002.
18. Nikolov A, Shopova E, Museva A, Dimitrov A. Vaginal Candida infection in the third trimester of pregnancy. Akush Ginekol (Sofiia). 2006; 45: 7-9.
19. Okungbowa FI, Isikhuemhen OS, Debe APO. The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Rev Iberoam Micol 2003; 20: 60-63.
20. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000-2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 2006; 49: 471-475.
21. Pirotta MV, Garland S. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics J Clin Microbiol 2006, 44: 3213-3217.
22. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, Sreenivas V, Kochupillai N. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30: 312-317.
23. Rivera-Sanchez R, Flores Paz R, Arriaga Alba M. Identificación de especies de Candida causantes de vaginitis en población mexicana. Enferm Infecc Microbiol Clin 2006; 24: 634-636.
24. Sánchez-Vargas LO, Ortiz-López NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, Lopez-Ribot JL, Gaitán-Cepeda LA, Quindós G. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol 2005; 22: 83-92.
25. Saporiti AM, Gomez D, Levalle S, Galeano M, Davel G, Vivot W, Rodero L. Candidiasis vaginal: etiología y perfil de sensibilidad frente a agentes antifúngicos de uso clínico. Rev Argent Microbiol 2001; 33: 217-222.
26. Sobel JD. Vulvovaginitis due to Candida glabrata: an emerging problem. Mycoses 1998; 41 (Suppl 2): S18-S22.
27. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR. Vulvovaginal candidiasis epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol 1998; 178: 203-211.
28. Staib P, Morschhauser J. Chlamydospore formation on Staib agar as a species specific characteristic of Candida dubliniensis. Mycoses 1999; 42: 521-524.
29. Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses 2006; 49: 523-524.